BI 1819479 clinical trials

A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).

This study is testing a new medicine, BI 1819479, for idiopathic pulmonary fibrosis (IPF). We want to see if it can slow down the lung scarring and if it's safe. Some people will get the medicine, others a dummy pill. We'll check how your breathing changes over about a year.